QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.104.069393v1 jpet.104.069393v2 jpet.104.069393v3 311/1/290    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Elmagbari, N. O. Articles by Bilsky, E. J. Search for Related Content PubMed PubMed Citation Articles by Elmagbari, N. O. Articles by Bilsky, E. J. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Pain

BEHAVIORAL PHARMACOLOGY

Antinociceptive Structure-Activity Studies with Enkephalin-Based Opioid Glycopeptides

Department of Biological Sciences (N.O.E., W.R.S.), University of Northern Colorado, Greeley, Colorado; Departments of Pharmacology (R.D.E., P.D., E.N., H.I.Y., F.P.) and Chemistry (M.M.P., M.D., C.M.K., V.J.H., R.P.), the University of Arizona, Tucson, Arizona; and Department of Pharmacology (J.J.L., E.J.B.), University of New England College of Osteopathic Medicine, Biddeford, Maine

Development of opioid peptides as therapeutic agents has historically been limited due to pharmacokinetic issues including stability and blood-brain barrier (BBB) permeability. Glycosylation of opioid peptides can increase peptide serum stability and BBB penetration. To further define the requirements for optimizing in vivo antinociceptive potency following intravenous administration, we synthesized a series of enkephalin-based glycopeptides using solid phase 9-fluorenylmethyloxy carbamate methods. The compounds differed in the sixth and subsequent amino acid residues (Ser or Thr) and in the attached carbohydrate moiety. In vitro binding and functional smooth muscle bioassays indicated that the addition of mono- or disaccharides did not significantly affect the opioid receptor affinity or agonist activity of the glycopeptides compared with their unglycosylated parent peptides. All of the glycopeptides tested produced potent antinociceptive effects in male ICR mice following intracerebroventricular injection in the 55°C tail-flick test. The calculated A₅₀ values for the Ser/Thr and monosaccharide combinations were all very similar with values ranging from 0.02 to 0.09 nmol. Selected compounds were administered to mice intravenously and tested for antinociception to indirectly assess serum stability and BBB penetration. All compounds tested produced full antinociceptive effects with calculated A ₅₀ values ranging from 2.2 to 46.4 µmol/kg with the disaccharides having potencies that equaled or exceeded that of morphine on a micromoles per kilogram basis. Substitution of a trisaccharide or bis- and tris-monosaccharides resulted in a decrease in antinociceptive potency. These results provide additional support for the utility of glycosylation to increase central nervous system bioavailability of small peptides and compliment our ongoing stability and blood-brain barrier penetration studies.

Address correspondence to: Dr. Edward Bilsky, Department of Pharmacology, University of New England College of Osteopathic Medicine, 11 Hills Beach Road, Stella Marris 323, Biddeford, Maine 04005. E-mail: ebilsky{at}une.edu

This article has been cited by other articles:

				G. P. Do Carmo, R. Polt, E. J. Bilsky, K. C. Rice, and S. S. Negus Behavioral Pharmacology of the {micro}/{delta} Opioid Glycopeptide MMP2200 in Rhesus Monkeys J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 939 - 948. [Abstract] [Full Text] [PDF]

				T. Buskas, S. Ingale, and G.-J. Boons Glycopeptides as versatile tools for glycobiology Glycobiology, August 1, 2006; 16(8): 113R - 136R. [Abstract] [Full Text] [PDF]